We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

32 hedge funds and large institutions have $38M invested in aTyr Pharma in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.03% less ownership

Funds ownership: 3.37% → 3.34% (-0.03%)

3% less capital invested

Capital invested by funds: $39.2M → $38M (-$1.14M)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

18% less funds holding

Funds holding: 39 → 32 (-7)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
32
Holders Change
-7
Holders Change %
-17.95%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
6
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$99K
2
Renaissance Technologies
Renaissance Technologies
New York
+$71.9K
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$51.8K
4
VKH
Virtu KCG Holdings
New York
+$35.7K
5
Morgan Stanley
Morgan Stanley
New York
+$15K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$117K
2
Millennium Management
Millennium Management
New York
-$103K
3
AIM
Alambic Investment Management
California
-$78K
4
DTL
Dynamic Technology Lab
Singapore
-$68K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$12.3M – – –
EC
2
EcoR1 Capital
California
$7.79M – – –
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$6.21M – – –
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$2.85M +$99K +2,115 +4%
BlackRock
5
BlackRock
New York
$1.84M -$117K -2,499 -6%
RSCM
6
Rock Springs Capital Management
Maryland
$1.61M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.5M +$655 +14 +0%
GHCM
8
Glen Harbor Capital Management
California
$529K – – –
MCIM
9
Meadow Creek Investment Management
Georgia
$435K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$375K -$11K -234 -3%
BCM
11
Bridgeway Capital Management
Texas
$354K – – –
EP
12
Elkfork Partners
Oregon
$342K – – –
RCM
13
Riverhead Capital Management
Delaware
$275K – – –
TAM
14
Tyers Asset Management
Texas
$249K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$205K +$71.9K +1,536 +55%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$201K – – –
Bank of America
17
Bank of America
North Carolina
$160K -$1.92K -41 -1%
Connor, Clark & Lunn Investment Management (CC&L)
18
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$152K +$3.32K +71 +2%
Northern Trust
19
Northern Trust
Illinois
$119K – – –
Morgan Stanley
20
Morgan Stanley
New York
$102K +$15K +320 +18%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$93K -$796 -17 -0.9%
QI
22
Quotient Investors
New York
$77K – – –
Goldman Sachs
23
Goldman Sachs
New York
$75K -$33.2K -709 -31%
Creative Planning
24
Creative Planning
Kansas
$58K -$4.03K -86 -7%
Janus Henderson Group
25
Janus Henderson Group
United Kingdom
$53K +$51.8K +1,107 New
1
2

ATYR Hedge Fund Activity: Q2 2017 in Review

32 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2017, worth a combined $38M — down 2.9% from $39.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ATYR and 2 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Alyeska Investment Group, adding an estimated $99K. The largest seller was BlackRock, cutting an estimated $117K.

  • 32 institutional investors held aTyr Pharma (ATYR) as of Q2 2017, down from 39 in Q1 2017.
  • Funds reported $38M of aTyr Pharma stock for Q2 2017, down 2.9% quarter-over-quarter.
  • 2 funds opened new aTyr Pharma positions in Q2 2017 and 8 closed out, a net change of -6 holders.
  • The largest aTyr Pharma buyer in Q2 2017 was Alyeska Investment Group, an estimated $99K added.
  • The largest aTyr Pharma seller in Q2 2017 was BlackRock, an estimated $117K sold.

Based on aggregated 13F filings for Q2 2017.